Meeting
2018 ASCO Annual Meeting
Outcomes of patients with nucleoplasmin 1 (NPM1) mutated acute myeloid leukemia (AML) treated with hypomethylating agents (HMAs).
Authors
Mahesh Swaminathan
University of Texas MD Anderson Cancer Center, Houston, TX
Mahesh Swaminathan , Elias Jabbour , Farhad Ravandi , Tapan M. Kadia , Gautam Borthakur , Marina Konopleva , Courtney Denton Dinardo , Sherry Pierce , Yesid Alvarado , Rita Elias Assi , Iman Adib Abou Dalle , Eran Tallis , Hagop M. Kantarjian , Guillermo Garcia-Manero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7054)
DOI
10.1200/JCO.2018.36.15_suppl.7054
Abstract #
7054
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
First Author: Michael Richard Grunwald
Poster
2017 ASCO Annual Meeting
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse.
First Author: Prajwal Boddu
Poster
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
First Author: Farhad Ravandi
Poster
2017 ASCO Annual Meeting
Response and survival rates with frontline hypomethylating agent (HMAs) in favorable risk AML.
First Author: Michael Richard Grunwald